Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.
Keywords: Endometrial cancer; Pathology; Prognosis; Stage.
Copyright © 2024 Elsevier Ltd. All rights reserved.